In a study of murine atopic dermatitis, pretreatment with KMF reduced CD69 (the earliest surface marker for activated T cells) expression and interleukin-2 (IL-2) production in activated Jurkat cells and murine CD4+ T cells, an effect attributed to its binding with multidrug resistance-associated protein 1 (MRP-1). Here, IL2 is linked to atopic eczema.